Global Prostate Cancer Therapeutics Market
Global Prostate Cancer Therapeutics Market

Prostate Cancer Therapeutics Comprehensive Study by Therapy (Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens), Chemotherapy (Systemic Therapy and Regional Chemotherapy), Biologic Therapy, Targeted Therapy), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online sales, Others)

Prostate Cancer Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2020- 2026 | CAGR: 8.41%  

Jan 2019 Edition 247 Pages 167 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned

The Players Covered in the Study are:
AstraZeneca [United Kingdom], Sanofi-Aventis [France], Ipsen [France], Tolmar [United States], Abbott [United States], Astellas Pharma [Japan], Indevus [United States], Dendreon [United States], Ferring [Switzerland], Bristol-Myers Squibb [United States], Pfizer [United States], Sanofi [France], Teva [Israel], Takeda [Japan] and Johnson & Johnson [United States]


Report Objectives / Segmentation Covered
By Therapy
  • Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
  • Chemotherapy (Systemic Therapy and Regional Chemotherapy)
  • Biologic Therapy
  • Targeted Therapy

By Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online sales
  • Others

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Factor Analysis
      • 3.1. Porters Five Forces
      • 3.2. Supply/Value Chain
      • 3.3. PESTEL analysis
      • 3.4. Market Entropy
      • 3.5. Patent/Trademark Analysis
    • 4. Global Prostate Cancer Therapeutics, by Therapy and Distribution Channels (value) (2013-2018)
      • 4.1. Introduction
      • 4.2. Global Prostate Cancer Therapeutics (Value)
        • 4.2.1. Global Prostate Cancer Therapeutics by: Therapy (Value)
          • 4.2.1.1. Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
          • 4.2.1.2. Chemotherapy (Systemic Therapy and Regional Chemotherapy)
          • 4.2.1.3. Biologic Therapy
          • 4.2.1.4. Targeted Therapy
        • 4.2.2. Global Prostate Cancer Therapeutics by: Distribution Channels (Value)
          • 4.2.2.1. Hospital Pharmacy
          • 4.2.2.2. Retail Pharmacy
          • 4.2.2.3. Online sales
          • 4.2.2.4. Others
    • 5. Prostate Cancer Therapeutics: Manufacturers/Players Analysis
      • 5.1. Competitive Landscape
        • 5.1.1. Market Share Analysis
          • 5.1.1.1. Top 3
          • 5.1.1.2. Top 5
      • 5.2. Peer Group Analysis (2018)
      • 5.3. BCG Matrix
      • 5.4. Company Profile
        • 5.4.1. AstraZeneca [United Kingdom]
          • 5.4.1.1. Business Overview
          • 5.4.1.2. Products/Services Offerings
          • 5.4.1.3. Financial Analysis
          • 5.4.1.4. SWOT Analysis
        • 5.4.2. Sanofi-Aventis [France]
          • 5.4.2.1. Business Overview
          • 5.4.2.2. Products/Services Offerings
          • 5.4.2.3. Financial Analysis
          • 5.4.2.4. SWOT Analysis
        • 5.4.3. Ipsen [France]
          • 5.4.3.1. Business Overview
          • 5.4.3.2. Products/Services Offerings
          • 5.4.3.3. Financial Analysis
          • 5.4.3.4. SWOT Analysis
        • 5.4.4. Tolmar [United States]
          • 5.4.4.1. Business Overview
          • 5.4.4.2. Products/Services Offerings
          • 5.4.4.3. Financial Analysis
          • 5.4.4.4. SWOT Analysis
        • 5.4.5. Abbott [United States]
          • 5.4.5.1. Business Overview
          • 5.4.5.2. Products/Services Offerings
          • 5.4.5.3. Financial Analysis
          • 5.4.5.4. SWOT Analysis
        • 5.4.6. Astellas Pharma [Japan]
          • 5.4.6.1. Business Overview
          • 5.4.6.2. Products/Services Offerings
          • 5.4.6.3. Financial Analysis
          • 5.4.6.4. SWOT Analysis
        • 5.4.7. Indevus [United States]
          • 5.4.7.1. Business Overview
          • 5.4.7.2. Products/Services Offerings
          • 5.4.7.3. Financial Analysis
          • 5.4.7.4. SWOT Analysis
        • 5.4.8. Dendreon [United States]
          • 5.4.8.1. Business Overview
          • 5.4.8.2. Products/Services Offerings
          • 5.4.8.3. Financial Analysis
          • 5.4.8.4. SWOT Analysis
        • 5.4.9. Ferring [Switzerland]
          • 5.4.9.1. Business Overview
          • 5.4.9.2. Products/Services Offerings
          • 5.4.9.3. Financial Analysis
          • 5.4.9.4. SWOT Analysis
        • 5.4.10. Bristol-Myers Squibb [United States]
          • 5.4.10.1. Business Overview
          • 5.4.10.2. Products/Services Offerings
          • 5.4.10.3. Financial Analysis
          • 5.4.10.4. SWOT Analysis
        • 5.4.11. Pfizer [United States]
          • 5.4.11.1. Business Overview
          • 5.4.11.2. Products/Services Offerings
          • 5.4.11.3. Financial Analysis
          • 5.4.11.4. SWOT Analysis
        • 5.4.12. Sanofi [France]
          • 5.4.12.1. Business Overview
          • 5.4.12.2. Products/Services Offerings
          • 5.4.12.3. Financial Analysis
          • 5.4.12.4. SWOT Analysis
        • 5.4.13. Teva [Israel]
          • 5.4.13.1. Business Overview
          • 5.4.13.2. Products/Services Offerings
          • 5.4.13.3. Financial Analysis
          • 5.4.13.4. SWOT Analysis
        • 5.4.14. Takeda [Japan]
          • 5.4.14.1. Business Overview
          • 5.4.14.2. Products/Services Offerings
          • 5.4.14.3. Financial Analysis
          • 5.4.14.4. SWOT Analysis
        • 5.4.15. Johnson & Johnson [United States]
          • 5.4.15.1. Business Overview
          • 5.4.15.2. Products/Services Offerings
          • 5.4.15.3. Financial Analysis
          • 5.4.15.4. SWOT Analysis
    • 6. Global Prostate Cancer Therapeutics Sale, by Therapy and Distribution Channels (value) (2019-2024)
      • 6.1. Introduction
      • 6.2. Global Prostate Cancer Therapeutics (Value)
        • 6.2.1. Global Prostate Cancer Therapeutics by: Therapy (Value)
          • 6.2.1.1. Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
          • 6.2.1.2. Chemotherapy (Systemic Therapy and Regional Chemotherapy)
          • 6.2.1.3. Biologic Therapy
          • 6.2.1.4. Targeted Therapy
        • 6.2.2. Global Prostate Cancer Therapeutics by: Distribution Channels (Value)
          • 6.2.2.1. Hospital Pharmacy
          • 6.2.2.2. Retail Pharmacy
          • 6.2.2.3. Online sales
          • 6.2.2.4. Others
    • 7. Appendix
      • 7.1. Acronyms
    • 8. Methodology and Data Source
      • 8.1. Methodology/Research Approach
        • 8.1.1. Research Programs/Design
        • 8.1.2. Market Size Estimation
        • 8.1.3. Market Breakdown and Data Triangulation
      • 8.2. Data Source
        • 8.2.1. Secondary Sources
        • 8.2.2. Primary Sources
      • 8.3. Disclaimer
    List of Tables
    • Table 1. Prostate Cancer Therapeutics: by Therapy(USD Million)
    • Table 2. Prostate Cancer Therapeutics: by Distribution Channels(USD Million)
    • Table 3. Company Basic Information, Sales Area and Its Competitors
    • Table 4. Company Basic Information, Sales Area and Its Competitors
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Prostate Cancer Therapeutics: by Therapy(USD Million)
    • Table 19. Prostate Cancer Therapeutics: by Distribution Channels(USD Million)
    • Table 20. Research Programs/Design for This Report
    • Table 21. Key Data Information from Secondary Sources
    • Table 22. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Prostate Cancer Therapeutics: by Therapy USD Million (2013-2018)
    • Figure 5. Global Prostate Cancer Therapeutics: by Distribution Channels USD Million (2013-2018)
    • Figure 6. Global Prostate Cancer Therapeutics share by Players 2018 (%)
    • Figure 7. Global Prostate Cancer Therapeutics share by Players (Top 3) 2018(%)
    • Figure 8. Global Prostate Cancer Therapeutics share by Players (Top 5) 2018(%)
    • Figure 9. BCG Matrix for key Companies
    • Figure 10. AstraZeneca [United Kingdom] Revenue, Net Income and Gross profit
    • Figure 11. AstraZeneca [United Kingdom] Revenue: by Geography 2018
    • Figure 12. Sanofi-Aventis [France] Revenue, Net Income and Gross profit
    • Figure 13. Sanofi-Aventis [France] Revenue: by Geography 2018
    • Figure 14. Ipsen [France] Revenue, Net Income and Gross profit
    • Figure 15. Ipsen [France] Revenue: by Geography 2018
    • Figure 16. Tolmar [United States] Revenue, Net Income and Gross profit
    • Figure 17. Tolmar [United States] Revenue: by Geography 2018
    • Figure 18. Abbott [United States] Revenue, Net Income and Gross profit
    • Figure 19. Abbott [United States] Revenue: by Geography 2018
    • Figure 20. Astellas Pharma [Japan] Revenue, Net Income and Gross profit
    • Figure 21. Astellas Pharma [Japan] Revenue: by Geography 2018
    • Figure 22. Indevus [United States] Revenue, Net Income and Gross profit
    • Figure 23. Indevus [United States] Revenue: by Geography 2018
    • Figure 24. Dendreon [United States] Revenue, Net Income and Gross profit
    • Figure 25. Dendreon [United States] Revenue: by Geography 2018
    • Figure 26. Ferring [Switzerland] Revenue, Net Income and Gross profit
    • Figure 27. Ferring [Switzerland] Revenue: by Geography 2018
    • Figure 28. Bristol-Myers Squibb [United States] Revenue, Net Income and Gross profit
    • Figure 29. Bristol-Myers Squibb [United States] Revenue: by Geography 2018
    • Figure 30. Pfizer [United States] Revenue, Net Income and Gross profit
    • Figure 31. Pfizer [United States] Revenue: by Geography 2018
    • Figure 32. Sanofi [France] Revenue, Net Income and Gross profit
    • Figure 33. Sanofi [France] Revenue: by Geography 2018
    • Figure 34. Teva [Israel] Revenue, Net Income and Gross profit
    • Figure 35. Teva [Israel] Revenue: by Geography 2018
    • Figure 36. Takeda [Japan] Revenue, Net Income and Gross profit
    • Figure 37. Takeda [Japan] Revenue: by Geography 2018
    • Figure 38. Johnson & Johnson [United States] Revenue, Net Income and Gross profit
    • Figure 39. Johnson & Johnson [United States] Revenue: by Geography 2018
    • Figure 40. Global Prostate Cancer Therapeutics: by Therapy USD Million (2013-2018)
    • Figure 41. Global Prostate Cancer Therapeutics: by Distribution Channels USD Million (2013-2018)
    Some of the key companies/manufacturers profiled in the report
    • AstraZeneca [United Kingdom]
    • Sanofi-Aventis [France]
    • Ipsen [France]
    • Tolmar [United States]
    • Abbott [United States]
    • Astellas Pharma [Japan]
    • Indevus [United States]
    • Dendreon [United States]
    • Ferring [Switzerland]
    • Bristol-Myers Squibb [United States]
    • Pfizer [United States]
    • Sanofi [France]
    • Teva [Israel]
    • Takeda [Japan]
    • Johnson & Johnson [United States]
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation